Screen for obstructive sleep apnea

Obstructive Sleep Apnoea (OSA): A Comprehensive Overview

1. Introduction

Obstructive sleep apnoea (OSA) is a common, potentially serious sleep‑disordered breathing (SDB) condition characterised by recurrent upper‑airway collapse during sleep, leading to intermittent hypoxia, hypercapnia, sleep fragmentation and arousals. The disorder exerts a profound impact on cardiovascular, metabolic, neurocognitive, and psychosocial health, contributing to reduced quality of life and increased health‑care utilisation. This article summarises current knowledge on the epidemiology, pathophysiology, clinical spectrum, diagnostic work‑up, severity grading, comorbidities, therapeutic strategies, and emerging concepts in OSA management—tailored for clinicians who routinely diagnose and treat sleep‑disordered breathing.

2. Epidemiology and Health Burden

Risk factors include obesity (body mass index ≥ 30 kg/m²), male sex, older age, craniofacial anatomic variants (short neck, macroglossia, enlarged tonsils), sedentary lifestyle, alcohol use, and certain ethnic groups (e.g., Hispanic, African‑American). The prevalence rises sharply with age after 50 years, reflecting both anatomical changes and increased comorbidities.

3. Pathophysiology

1. Upper Airway Mechanics – The pharyngeal dilator muscles (genioglossus, levator veli palatini) maintain airway patency during inspiration. In OSA these muscles fail to generate adequate force secondary to:

• Reduced neuromuscular drive (sleep‑related hypophasis of ventilation).
• Anatomical narrowing (excess adipose tissue around the pharyngeal walls, posterior tongue enlargement).

1. Collapsibility Index – The critical closing pressure (P_crit) is the negative pressure at which airway collapse occurs. OSA patients have a more negative P_crit due to reduced muscle bulk and increased tissue compliance.
2. Ventilatory Control Instability – Cyclic hypoxia triggers chemoreflex‐mediated arousals, restoring ventilation but fragmenting sleep architecture (N3 → N2 → wake). This results in the classic “hypopnea‑arousal” pattern on polysomnography (PSG).
3. Systemic Consequences – Repetitive oxyhaemoglobin desaturation (nadir SpO₂ < 80 % in severe cases) leads to:

• Oxidative stress and inflammation → endothelial dysfunction.
• Sympathetic activation → chronic hypertension, arrhythmias.
• Metabolic derangements → insulin resistance, dyslipidaemia.

1. Genetic & Molecular Influences – Genome‑wide association studies have identified loci near PDE4D, GAL and FUT3 that modulate airway muscle tone and inflammatory pathways (see [5]).

4. Clinical Presentation

Red‑flag features that warrant urgent evaluation include:

• Hypertension resistant to treatment.
• Atrial fibrillation or other arrhythmias.
• Pulmonary hypertension.
• Congestive heart failure (especially with reduced ejection fraction).
• Subtle neurocognitive decline in elderly patients.

Physical examination may reveal:

• Body mass index ≥ 30 kg/m².
• Neck circumference > 40 cm (men) or > 38 cm (women).
• Macroglossia, uvular redundancy, enlarged tonsils, soft palate hypertrophy.
• Nasal obstruction (deviated septum, turbinate hypertrophy).

5. Diagnostic Approach

5.1 Polysomnography (PSG) – Gold Standard

• Technical requirements – At least 7 channels (EEG, EOG, EMG, ECG, respiratory effort, thoracic/abdominal movement, nasal airflow, SpO₂).
• AHI definition – Number of obstructive apnoeas + hypopneas (duration ≥ 10 s for hypopnea with ≥ 4% desaturation) per hour of total sleep time (TST).

• Criteria for OSA diagnosis – AHI ≥ 5 with symptoms, or AHI ≥ 15 regardless of symptoms (AASM 2020 guidelines) [6].

5.2 Home Sleep Apnea Testing (HSAT)

Indications: low to moderate pre‑test probability, primary‑care setting, patients without significant comorbidities (e.g., COPD, central sleep apnoea). Devices must meet AASM criteria for pressure, flow, and oximetry; ≥ 70 % of total sleep time recorded.

5.3 Screening Tools

• STOP‑BANG – ≥4 positive items have a sensitivity of ~85 % for moderate–severe OSA (specificity ≈70 %). [7]
• OSA500, Lund Apnea Risk Matrix – useful in research or high‑throughput clinics.

5.4 Ancillary Tests

• Nocturnal pulse oximetry – limited utility; not diagnostic but may support suspicion when PSG unavailable.
• CT/MR imaging of airway – reserved for pre‑surgical planning or atypical presentations (e.g., neuromuscular disease).

6. Severity Grading and Prognostic Markers

Beyond AHI, several “phenotypes” have been described that influence prognosis and treatment response:

Biomarkers (e.g., plasma C‑reactive protein, soluble ST2, fibroblast growth factor 21) have shown incremental prognostic value in recent cohort studies but are not yet incorporated into routine practice [8].

7. Comorbidities and Systemic Impact

8. Management Principles

8.1 First‑Line Therapy: Continuous Positive Airway Pressure (CPAP)

• Indication – All patients with moderate–severe OSA (AHI ≥ 15) and symptomatic patients; also consider in asymptomatic severe disease per AASM 2020 [6].
• Titration strategies
• Fixed‑pressure CPAP – Titrated during a diagnostic night (usually 4–6 cm H₂O steps).
• Auto‑titrating CPAP (Auto‑CPAP) – Adjusts pressure within a pre‑set range (e.g., 4–20 cm H₂O) based on respiratory events; non‑inferior to fixed‑pressure for most outcomes [13].
• Pressure prescription – Target 95th percentile of AHI‑derived pressures or at least 6 cm H₂O above the 4% desaturation point.

8.2 Adherence and Monitoring

• Adherence threshold – ≥ 70 % of total nighttime use (≥ 4 h/night) for benefit; objective data (downloaded device logs, Bluetooth transmission) are preferred over self‑report.
• Problem‑solving strategies – mask fit adjustments, heated humidification, pressure ramps, addressing claustrophobia or nasal congestion.

8.3 Adjunctive Non‑Pharmacologic Therapies

8.4 Management of Specific Patient Subgroups

9. Follow‑Up and Long‑Term Outcomes

• Objective adherence data – downloade​d device reports at 1‑month, 3‑month, then every 6–12 months.
• Symptom reassessment – Epworth Sleepiness Scale (ESS) or OSA500 questionnaire at each visit; aim for ESS ≤ 8 after treatment.
• Biomedical monitoring – repeat AHI only if clinical status changes, CPAP pressure adjustment is needed, or there is suspicion of non‑adherence/weight gain.
• Cardiovascular risk reduction – aggressive control of hypertension and diabetes; OSA treatment alone reduces systolic BP by ~4–7 mmHg (meta‑analysis) [19].

10. Emerging Concepts & Future Directions

1. Phenotype‑Driven Therapy – Utilising machine‑learning algorithms on baseline PSG data to predict response to CPAP vs. oral appliance vs. surgery (e.g., “high‑gain” versus “low‑gain” phenotypes) [20].
2. Closed‑Loop Adaptive Servo‑Ventilation (ASV) – Early trials suggest benefit in patients with CSA/OSA overlap, though caution is required in heart failure due to potential worsening of ventilation instability [21].
3. Biomarker Panels – Combining circulating miRNAs (e.g., miR‑146a) and inflammatory markers may identify high‑risk individuals for earlier intervention.
4. Telemedicine & Remote Monitoring – Home HSAT followed by tele‑CPAP titration has been shown to be non‑inferior to in‑lab studies, expanding access especially in rural settings [22].

11. Key Guideline References (selected)